Sourcing and Negotiating Deals with Big BioPharma March 20, 2008

Sourcing and Negotiating Deals with Big BioPharma

Agenda:
3:00-3:30 PM Networking, Registration & Tour
3:30-5:00 PM Expert Panel
5:00-6:30 PM Networking Reception

From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them.

Questions that will be raised include:
- What are the best approaches for identifying a good partner?
- What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A?
- What about the rising of Big Pharma VC Funds?
- What are the strategies for attracting, securing and structuring strategic investments?
- How the Larger Bio-Companies' needs differ from VCs' needs?
- What are the key contract terms to be negotiated?
- What are the strategic reasoning behind different kinds partnerships?
- Effects on existing and potential future collaboration partners and other strategic decisions.
- Pros and cons of a small company partnering with a larger company.
- "Dos" and "don'ts" of managing these important relationships

Invited Speakers
- Campbell Murray, Managing Director, Novartis BioVenture Fund
- Robert Cohen, Senior Director-Oncology Strategy, Business Development, Genentech, Inc.
- Barbara Yanni, VP & Chief Licensing Officer, Merck & Co., Inc.
- Anton Gueth, Managing Director, Merchant Banking, Burrill & Company
- David Summa, President & CEO, Acumen Pharmaceuticals
- Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP

Regular $60 | Partners' Network $40 | Members: Free | Door Registration: add $10.

Official Website: http://www.sjbiocenter.com/event/ev_2008Q1-SourcingAndNegotiatingDealsWithBigBioPharma.html